Further clinical evaluation of AR in pancreatic cancer is currently underway in a phase I study evaluating AR in combination with checkpoint inhibition and gemcitabine in advanced pancreatic cancer (NCT03816358). Here, AR is linked to familial pancreatic carcinoma.